Novartis Replaces Japan Unit Head Amid Clinical Trial Probe
This article is for subscribers only.
Novartis AG named Dirk Kosche as head of its Japan business, replacing Yoshiyasu Ninomiya after investigations showed that the unit involved itself in drug studies that were supposed to be independent of the company.
Novartis needs to rebuild a Japanese business that meets “legal obligations and executes operations ethically” under new management, the Basel, Switzerland-based drugmaker’s Japanese unit said in a statement today.